319 related articles for article (PubMed ID: 33329517)
1. Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data.
Liu Q; Cheng R; Kong X; Wang Z; Fang Y; Wang J
Front Immunol; 2020; 11():558757. PubMed ID: 33329517
[TBL] [Abstract][Full Text] [Related]
2. TIGIT-related transcriptome profile and its association with tumor immune microenvironment in breast cancer.
Zhang Q; Gao C; Shao J; Wang Z
Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33721026
[TBL] [Abstract][Full Text] [Related]
3. JAK2 expression is correlated with the molecular and clinical features of breast cancer as a favorable prognostic factor.
Liu Q; Ai B; Kong X; Wang X; Qi Y; Wang Z; Fang Y; Wang J
Int Immunopharmacol; 2021 Jan; 90():107186. PubMed ID: 33290964
[TBL] [Abstract][Full Text] [Related]
4. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
Wen WX; Leong CO
PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
[TBL] [Abstract][Full Text] [Related]
5. Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Jul; 8(29):47400-47411. PubMed ID: 28537889
[TBL] [Abstract][Full Text] [Related]
6. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer.
Chen Q; Pu N; Yin H; Zhang J; Zhao G; Lou W; Wu W
J Cell Mol Med; 2020 Aug; 24(15):8674-8686. PubMed ID: 32643277
[TBL] [Abstract][Full Text] [Related]
7. Seven immune-related genes prognostic power and correlation with tumor-infiltrating immune cells in hepatocellular carcinoma.
Liu T; Wu H; Qi J; Qin C; Zhu Q
Cancer Med; 2020 Oct; 9(20):7440-7452. PubMed ID: 32815653
[TBL] [Abstract][Full Text] [Related]
8. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
Liu D; Yang X; Wu X
Front Immunol; 2021; 12():663495. PubMed ID: 34025664
[TBL] [Abstract][Full Text] [Related]
9. Identification of an immune signature to predict poor clinical outcome in cervical cancer.
Yan W; Jin H; Zhang X; Long S; Xia Q; Meng D; Ding B; Li D; Ma J; Cao J; Wang S
Epigenomics; 2021 Jun; 13(11):891-907. PubMed ID: 33955785
[No Abstract] [Full Text] [Related]
10. Transcriptomic signatures of tumors undergoing T cell attack.
Gokuldass A; Schina A; Lauss M; Harbst K; Chamberlain CA; Draghi A; Westergaard MCW; Nielsen M; Papp K; Sztupinszki Z; Csabai I; Svane IM; Szallasi Z; Jönsson G; Donia M
Cancer Immunol Immunother; 2022 Mar; 71(3):553-563. PubMed ID: 34272988
[TBL] [Abstract][Full Text] [Related]
11. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
[TBL] [Abstract][Full Text] [Related]
12. ATP2C2 Has Potential to Define Tumor Microenvironment in Breast Cancer.
Liu J; Wei Y; Wu Y; Li J; Sun J; Ren G; Li H
Front Immunol; 2021; 12():657950. PubMed ID: 33936088
[TBL] [Abstract][Full Text] [Related]
13. Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Kim A; Lim SM; Kim JH; Seo JS
Front Immunol; 2021; 12():598671. PubMed ID: 33717076
[TBL] [Abstract][Full Text] [Related]
14. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
Front Immunol; 2021; 12():688215. PubMed ID: 34305920
[TBL] [Abstract][Full Text] [Related]
15. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
16. Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses.
Zhang B; Yang L; Wang X; Fu D
Gene; 2021 Jan; 764():145105. PubMed ID: 32882333
[TBL] [Abstract][Full Text] [Related]
17. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
[TBL] [Abstract][Full Text] [Related]
18. The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness.
Wang Z; Guo X; Gao L; Deng K; Lian W; Bao X; Feng M; Duan L; Zhu H; Xing B
J Clin Endocrinol Metab; 2020 Sep; 105(9):e3207-23. PubMed ID: 32652004
[TBL] [Abstract][Full Text] [Related]
19. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
20. Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples.
Liu Q; Qi Y; Zhai J; Kong X; Wang X; Wang Z; Fang Y; Wang J
Front Immunol; 2021; 12():599207. PubMed ID: 34267742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]